CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies
Author:
Affiliation:
1. Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle Washington USA
2. Department of Medicine; University of Washington; Seattle Washington USA
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference43 articles.
1. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail;Stamenkovic;J. Exp. Med.,1988
2. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia;Davila;Sci. Transl. Med.,2014
3. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells;Kochenderfer;Blood,2012
4. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial;Lee;Lancet,2015
5. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N. Engl. J. Med.,2014
Cited by 66 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Chimeric Antigen Receptor T-Cell Postinfusion Fever: Infection Profile, Clinical Parameters, and Biomarkers Trends to Assist Antibiotic Stewardship;Open Forum Infectious Diseases;2024-06-28
2. Post-CART-T Cell Infection: Etiology, pathogenesis, and therapeutic approaches;Revista Española de Quimioterapia;2023-11-24
3. Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T‐cell therapy;European Journal of Haematology;2023-10-25
4. Targeted cellular therapy for treatment of relapsed or refractory leukemia;Best Practice & Research Clinical Haematology;2023-09
5. Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy;2023-06-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3